Skip to main content
    O

    OraSure Technologies Inc (OSUR)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $3.60
    -0.02 (-0.55%)

    Market Cap: $249.95M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    OraSure Technologies Inc (OSUR) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    OraSure Technologies (OSUR) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, OraSure Technologies reported EPS of -$0.18, above the -$0.22 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    60%(24/40)
    Avg Surprise
    +43.66%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.18
    Range-$0.18 - -$0.18
    4 analysts
    Revenue Consensus
    $30.05M
    Range$27.37M - $32.55M
    4 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.13
    Range-$0.17 - -$0.09
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.15+10.7%
    60d ago-$0.15+10.7%
    30d ago-$0.15+10.7%
    7d ago-$0.17+23.8%
    Current-$0.13
    Revenue Consensus
    $29.76M
    Range$29.53M - $30.00M
    2 analysts

    Next Report

    OSUR has an expected report date of Feb 23, 2027.

    OSUR Earnings Call

    The latest OSUR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, OSUR beat 24, missed 14 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $30.91M, up 14.1% from $27.09M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.18-$0.22N/A+18.18%BeatN/A11 up, 0 downNov 9, 2026$30.91M
    Jun 30, 2026-$0.23-$0.22-$0.22 - -$0.22-4.55%MissN/A10 up, 2 downAug 5, 2026$30.64M
    Mar 31, 2026-$0.24-$0.17-$0.19 - -$0.14-41.18%MissN/A20 up, 1 downMay 6, 2026$27.93M
    Dec 31, 2025-$0.19-$0.19N/A0.00%In lineN/A30 up, 1 downFeb 25, 2026$26.76M
    Sep 30, 2025-$0.17-$0.20N/A+15.00%BeatN/A20 up, 3 downNov 5, 2025$27.09M
    Jun 30, 2025-$0.19-$0.15-$0.16 - -$0.14-26.67%Miss-371.4%30 up, 1 downAug 5, 2025$31.24M
    Mar 31, 2025-$0.18-$0.12-$0.15 - -$0.08-50.00%Miss-550.0%41 up, 0 downMay 7, 2025$29.93M
    Dec 31, 2024-$0.06-$0.01-$0.03 - $0.01-460.75%Miss-122.2%5N/AFeb 25, 2025$37.45M
    Sep 30, 2024-$0.01-$0.02N/A+50.00%Beat-103.7%30 up, 0 downNov 6, 2024$39.91M
    Jun 30, 2024$0.07$0.03N/A+133.33%Beat-22.2%20 up, 0 downAug 6, 2024$54.34M
    Mar 31, 2024$0.04$0.03-$0.05 - $0.06+33.33%Beat-91.5%40 up, 0 downMay 8, 2024$54.13M
    Dec 31, 2023$0.27$0.09$0.06 - $0.12+200.00%Beat-25.0%40 up, 0 downFeb 27, 2024$75.88M
    Sep 30, 2023$0.27$0.08-$0.03 - $0.12+237.50%Beat+107.7%40 up, 0 downNov 7, 2023$89.19M
    Jun 30, 2023$0.09-$0.08-$0.11 - -$0.03+212.50%BeatN/A30 up, 1 downAug 3, 2023$85.44M
    Mar 31, 2023$0.47$0.14$0.09 - $0.22+235.71%BeatN/A30 up, 0 downMay 10, 2023$154.96M
    Dec 31, 2022$0.36$0.04N/A+800.00%BeatN/A30 up, 0 downFeb 14, 2023$123.08M
    Sep 30, 2022$0.13$0.03N/A+333.33%BeatN/A30 up, 0 downNov 8, 2022$116.46M
    Jun 30, 2022-$0.04-$0.11-$0.20 - -$0.07+63.64%BeatN/A50 up, 0 downAug 9, 2022$80.23M
    Mar 31, 2022-$0.28-$0.13-$0.18 - $0.16-115.38%Miss-660.0%60 up, 0 downMay 10, 2022$67.71M
    Dec 31, 2021-$0.14-$0.13-$0.27 - -$0.07-7.69%Miss-566.7%60 up, 0 downFeb 23, 2022$63.57M
    Sep 30, 2021-$0.22-$0.05-$0.12 - $0.05-340.00%Miss-2300.0%7N/ANov 3, 2021$53.92M
    Jun 30, 2021-$0.02$0.04-$0.02 - $0.08-150.00%MissN/A6N/AAug 3, 2021$57.61M
    Mar 31, 2021$0.05$0.03$0.01 - $0.10+66.67%BeatN/A7N/AMay 5, 2021$58.58M
    Dec 31, 2020$0.03$0.07$0.03 - $0.10-57.14%Miss-50.0%6N/AMar 1, 2021$62.85M
    Sep 30, 2020$0.01-$0.06-$0.11 - $0.00+116.67%Beat-66.7%6N/ANov 4, 2020$48.01M
    Jun 30, 2020-$0.17-$0.07-$0.14 - -$0.07-142.86%Miss-342.9%4N/AAug 5, 2020$29.26M
    Mar 31, 2020-$0.10-$0.05-$0.07 - -$0.05-100.00%MissN/A2N/AMay 6, 2020$31.60M
    Dec 31, 2019$0.06$0.07$0.07 - $0.07-14.29%Miss-70.0%2N/AFeb 19, 2020$49.67M
    Sep 30, 2019$0.03$0.13$0.03 - $0.20-76.92%Miss-76.9%3N/ANov 6, 2019$35.99M
    Jun 30, 2019$0.07$0.03$0.02 - $0.03+133.33%Beat-36.4%2N/AAug 6, 2019$38.83M
    Mar 31, 2019-$0.02-$0.06-$0.06 - -$0.06+66.67%Beat-128.6%4N/AMay 8, 2019$30.12M
    Dec 31, 2018$0.20$0.11$0.11 - $0.11+81.82%Beat+66.7%4N/AFeb 6, 2019$50.25M
    Sep 30, 2018$0.13$0.11N/A+18.18%Beat+44.4%N/AN/ANov 7, 2018$45.88M
    Jun 30, 2018$0.11$0.07N/A+57.14%Beat+22.2%4N/AAug 8, 2018$43.63M
    Mar 31, 2018$0.07$0.05N/A+40.00%Beat+40.0%4N/AMay 2, 2018$41.99M
    Dec 31, 2017$0.12$0.11$0.09 - $0.13+9.09%Beat-7.7%5N/AFeb 7, 2018$52.03M
    Sep 30, 2017$0.09$0.09$0.09 - $0.100.00%In line-18.2%5N/ANov 1, 2017$42.31M
    Jun 30, 2017$0.09$0.07$0.07 - $0.08+28.57%Beat+28.6%5N/AAug 2, 2017$40.18M
    Mar 31, 2017$0.05-$0.03N/A+266.67%Beat+25.0%N/AN/AMay 3, 2017$32.55M
    Dec 31, 2016$0.13$0.06N/A+116.67%Beat+62.5%N/AN/AFeb 8, 2017$35.50M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.73, after $0.04 the year before. It was $0.35 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.73-1925.0%
    Dec 31, 2024$0.04-96.4%
    Dec 31, 2023$1.10+547.1%
    Dec 31, 2022$0.17N/A
    Dec 31, 2021-$0.33N/A
    Dec 31, 2020-$0.23-264.3%
    Dec 31, 2019$0.14-72.5%
    Dec 31, 2018$0.51+45.7%
    Dec 31, 2017$0.35N/A
    Dec 31, 2016$0.35N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,1886
    2026Q2Jun 30, 20263,4105
    2026Q1Mar 31, 20262,4706
    2025Q4Dec 31, 20253,4067
    2025Q3Sep 30, 20253,0565
    2025Q2Jun 30, 20253,6346
    2025Q1Mar 31, 20255,2857
    2024Q4Dec 31, 20245,6889

    2026Q3 Earnings Call

    Opening remarks

    Mike Vallie Investor Relations Good afternoon, and welcome to OraSure Technologies Third Quarter 2026 Earnings Call. Participating in the call for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer, and Ken McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded, and the recording can be found on our Investor Relations website. Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, cash flows and other financial performance, product development, performance, shipments and markets, business plans, regulatory filings and approvals, expectations and strategies. Actual results could be significantly different. Factors that could affect results are discussed more fully in OraSure's SEC filings, its annual report on Form 10-K for the year ended December 31, 2025, its quarterly reports on Form 10-Q, and its other SEC filings. Although forward-looking statements help to provide more complete information about future prospects, listeners should keep in mind that forward-looking statements are based solely on information available to management as of today. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after this call. In addition, the call will also discuss certain non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in our earnings press release issued today, which is available on the Investor Relations section of our website. With that, I'm pleased to turn the call over to Carrie.

    Carrie Eglinton Manner President and CEO Thanks, Mike, and thank you to everyone for joining us. Today, I'll discuss some highlights from Q3 and provide updates on our key priorities for the balance of 2026 and our outlook for 2027. Q3 was another solid quarter of execution and our return to growth. We delivered 14% year-over-year growth and 1% sequential growth, meaningfully expanded gross margins and reduced operating spend, results driven by continued execution of our strategy. Continuing now with more on each of our portfolios. In International Diagnostics, our Q3 performance reflected our approach to stabilize, diversify and localize our business. We are building on our long-standing leadership in HIV testing while expanding our portfolio and strengthening partnerships that broaden our reach and enable us to address critical public health needs across Africa, Latin America and other international markets. Starting with Ebola. As discussed last quarter, in July, we received FDA emergency use authorization for our OraQuick Ebola 2.0 rapid antigen test. The test detects all four Ebola virus species known to cause human disease, including Bundibugyo, the species responsible for the current outbreak. Since the outbreak began, its scale and geographic reach have increased dramatically.

    Frequently Asked Questions About OSUR

    When is OraSure Technologies's next earnings date?

    OraSure Technologies's next earnings report is expected for Feb 23, 2027.

    Did OSUR beat earnings estimates last quarter?

    Yes. OraSure Technologies reported EPS of -$0.18 for the quarter ended Sep 30, 2026, above the -$0.22 estimate, a 18.18% surprise.

    What EPS do analysts expect from OSUR next quarter?

    The consensus EPS estimate for OraSure Technologies for the quarter ending Dec 31, 2026 is -$0.18 from 4 analysts, with estimates from -$0.18 to -$0.18.

    How often does OSUR beat earnings estimates?

    OraSure Technologies beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -68.74%.